Kostine, Marie https://orcid.org/0000-0002-6729-6200
Finckh, Axel https://orcid.org/0000-0002-1210-4347
Bingham, Clifton O
Visser, Karen
Leipe, Jan
Schulze-Koops, Hendrik
Choy, Ernest H
Benesova, Karolina
Radstake, Timothy R D J
Cope, Andrew P
Lambotte, Olivier
Gottenberg, Jacques-Eric https://orcid.org/0000-0002-9469-946X
Allenbach, Yves https://orcid.org/0000-0002-3185-7993
Visser, Marianne
Rusthoven, Cindy
Thomasen, Lone
Jamal, Shahin
Marabelle, Aurélien
Larkin, James
Haanen, John B A G
Calabrese, Leonard H https://orcid.org/0000-0002-1789-4923
Mariette, Xavier
Schaeverbeke, Thierry
Clinical trials referenced in this document:
Documents that mention this clinical trial
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
https://doi.org/10.1136/annrheumdis-2020-217139
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications
https://doi.org/10.1136/annrheumdis-2019-216510
Funding for this research was provided by:
European League Against Rheumatism
This article is maintained by: Elsevier
Article Title: EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2020-217139
Content Type: article
Copyright: Copyright © 2021 © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.